Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 5INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 15Head & Neck 7Gastrointestinal 5Tumor-Agnostic 4Genitourinary 3Endocrine 3Breast 3Plasma cell 1Other solid neoplasm 1Gynecologic 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Advanced Breast Cancer 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × vandetanib × Breast × Clear all
NCT00752986 2016-12-05

ZACFAST

Sanofi

Phase 2 Terminated
39 enrolled 7 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00494481 2016-09-30

E3 Breast Cancer Taxotere Combination

Sanofi

Phase 2 Completed
64 enrolled 7 charts
Breast

Advanced Breast Cancer

NCT00034918 2016-08-24

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

Sanofi

Phase 2 Completed
44 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡